The linked FDA records identify Neptune Medical, Inc. as applicant on two traditional 510(k) clearances decided in September 2026. The Pathfinder Endoscope Overtube, K262262, was received July 2, 2026 and decided September 18, 2026 under product code FED. The Triton 1 System, K260503, was received February 17, 2026 and decided September 3, 2026 under product code FDF. Both carry a Substantially Equivalent decision and a Summary statement. The MedtechLedger collection holds two linked 510(k) records, both with SESE decisions, and the smaller record sample shows the same two SESE decisions. [1][2][3][5]

Pathfinder Endoscope Overtube (K262262)

The Pathfinder Endoscope Overtube is regulated as an Endoscope And Accessories device under 21 CFR 876.1500, Class II, product code FED, with the openFDA device name Endoscopic Access Overtube, Gastroenterology-Urology. The clearance letter is addressed to Neptune Medical, Inc. care of a regulatory affairs consultant at AlvaMed, Inc. in Needham, Massachusetts, and lists the device as dated and received July 2, 2026. The decision date is September 18, 2026, clearance type Traditional, third-party review flagged No. [1][3]

The determination summary lists bench testing covering elongation and compression, endoscope trackability, surface contamination and defects, bonds and handle tensile, handle cantilever torque, and endoscope with distal cap trackability. The same summary states that no animal or clinical studies were conducted for this submission. The FDA database entry for K262262 was last updated November 9, 2026. [3][4]

Triton 1 System (K260503)

The Triton 1 System is regulated under the same regulation number, 21 CFR 876.1500, Class II, with product codes FDF, FED and FET. The clearance letter is addressed to a senior manager for quality assurance and regulatory compliance at Neptune Medical, Inc. in Burlingame, California, and gives a device date of July 31, 2026. The FDA record shows receipt February 17, 2026 and a September 3, 2026 decision, Traditional clearance, no third-party review. [2][5]

The determination summary compares the Triton 1 System (K260503) with a predicate, the Evis Exera II 180 System (K100584), both under regulation 876.1500, Class II. The stated indications describe visualization and diagnostic or therapeutic access to the adult lower gastrointestinal tract, including the anus, rectum, sigmoid colon, colon, cecum and ileocecal valve, for endoscopy and endoscopic surgery. [5]

Technology as described by the publisher

Neptune Medical’s website describes technology intended for endoscope control during gastrointestinal procedures. The GI Pathfinder site describes an overtube with separate microcomposite layers in its walls that change between flexible and rigid states using vacuum. These are the publishers’ product descriptions and should be distinguished from the decision scope recorded in the FDA filings. [8][9][10]

The same company site states that Pathfinder is its first FDA-cleared product and that Triton is a GI robotic endoscopy system. The GI Pathfinder product page carries physician commentary attributed to named clinicians at Northwestern University and the University of California, Irvine, and notes that federal law restricts sale by or on the order of a physician. [6][8]

What the filings do and do not establish

Both clearances are substantial-equivalence determinations supported by bench testing and a Summary statement; the Pathfinder summary explicitly reports no animal or clinical studies. The cited FDA records do not establish manufacturing sites, ownership structure, pricing, hospital customers or post-market performance. The two linked 510(k) records and two SESE decisions describe this collection as retrieved, not total company sales or portfolio size. [1][2][3][5]